Steven Cohen Atea Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $117,720 - $185,565	-36,673 Reduced 99.98%	9 $0
Q1 2023 May 15, 2023	BUY	$3.0 - $4.97 $110,046 - $182,309	36,682 New	36,682 $122,000
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $2.55 Million - $14.8 Million	-332,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $7.09 Million - $11.6 Million	332,200 New	332,200 $11.6 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.